1 **Polycystic ovary syndrome is associated with adverse mental health and**

2 **neurodevelopmental outcomes**

3

4 Thomas R. Berni, Christopher L. Morgan, Ellen R. Berni, D. Aled Rees.

5

6

7 Pharmatelligence (T.R.B, C.L.M, E.R.B.), Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ,

8 United Kingdom; Institute of Primary Care and Public Health (C.L.M.) and Neuroscience and

9 Mental Health Research Institute (D.A.R.), School of Medicine, Cardiff University, Cardiff

10 CF24 4HQ, United Kingdom

11

12 **Abbreviated title:** Mental health outcomes in PCOS

13 **Keywords:** Polycystic ovary syndrome; depression; anxiety; autism; attention deficit

14 hyperactivity disorder; bipolar disorder

15 **Word count:** 3572

16 **Number of tables:** 4

17 **Number of figures:** 2

18

19 **Corresponding author and person to whom reprint requests should be addressed:**

20 Aled Rees, Neuroscience and Mental Health Research Institute, School of Medicine, Cardiff

21 University, Heath Park, Cardiff CF24 4HQ, United Kingdom

22 Email: reesda@cf.ac.uk

23 Telephone: +44 (0)2920 742309 Fax: +44 (0)2920 744671

24

25 **Disclosure statement:** The authors report no conflicts of interest in this work.

26

27
28
29
30
31

Abstract

Context

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and subfertility but the effects on mental health and child neurodevelopment are unclear.

Objectives

To determine if (i) there is an association between PCOS and psychiatric outcomes, and (ii) whether rates of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) are higher in children of mothers with PCOS.

Design

Data were extracted from the Clinical Practice Research Datalink. Patients with PCOS were matched to two control sets (1:1) by age, BMI and primary care practice. Control set 2 was additionally matched on prior mental health status. Primary outcomes were the incidence of depression, anxiety and bipolar disorder. Secondary outcomes were the prevalence of ADHD or ASD in the children.

Results

16,986 eligible patients were identified; 16,938 and 16,355 were matched to control sets 1 and 2 respectively. Compared to control set 1, baseline prevalence was 23.1% versus 19.3% for depression, 11.5% versus 9.3% for anxiety and 3.2% versus 1.5% for bipolar disorder (p<0.001). The hazard ratio for time to each endpoint was 1.26 (95% CI 1.19-1.32), 1.20 (1.11-1.29) and 1.21 (1.03-1.42) for set 1, and 1.38 (1.30-1.45), 1.39 (1.29-1.51) and 1.44 (1.21-1.71) for set 2. The odds ratios for ASD and ADHD in children were 1.54 (1.12-2.11) and 1.64 (1.16-2.33) for set 1, and 1.76 (1.27-2.46) and 1.34 (0.96-1.89) for set 2.

Conclusions

PCOS is associated with psychiatric morbidity and increased risk of ADHD and ASD in their children. Screening for mental health disorders should be considered during assessment.

62 **Précis**

63 Analysis of 17,000 patients with PCOS and controls found an increased incidence of

64 psychiatric morbidity in women with PCOS, and increased risk of autism spectrum disorder

65 and ADHD in their children.

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Introduction

Polycystic Ovary Syndrome is the commonest endocrine condition affecting young women, and is characterized by hyperandrogenism, menstrual disturbance and subfertility. In addition to its well-recognized reproductive sequelae (1), PCOS is now established as a metabolic disorder underpinned by insulin resistance and leading to an increased risk of type 2 diabetes (2).

The cutaneous manifestations of hyperandrogenism, including hirsutism, acne and scalp hair loss, are emotionally distressing (3, 4), and could contribute to an increased prevalence of depression and anxiety in this population (5-8). Comorbid mental health disorders have also been shown to contribute to impaired quality of life in PCOS (9). However, it is difficult to establish how many of these outcomes are attributable to PCOS *per se*, and how many to obesity, which is common in this patient group and itself associated with adverse mental health outcomes, including depression (10) and anxiety (11). This risk of depression may be particularly increased in patients with metabolically unhealthy obesity, which is characterized by insulin resistance and abdominal adiposity (12), compared to metabolically healthy weight-matched controls (13, 14). Furthermore, in community-based studies, the association between obesity and depression appears stronger for women compared to men (15). This association may be bi-directional: in longitudinal studies obesity increases the risk of a subsequent diagnosis of depressive disorder, whilst depression at baseline in turn increases the odds for developing obesity (16). This latter risk appears to be particularly high for adolescent females (16).

Whilst previous studies have focused on the risk of depressive disorder and anxiety in patients with PCOS, hyperandrogenism may also influence the risk of other mental health disorders including schizophrenia (17). However, a recent population-based cohort study failed to demonstrate an increased risk of developing schizophrenia (or bipolar disorder) in women with PCOS, although an increased risk of depressive disorder, anxiety disorder and sleep disorder was confirmed (18). Other studies have shown that the risk of eating disorder, notably binge-eating disorder, may be increased in women with PCOS (19, 20). Attention deficit hyperactivity disorder (ADHD) has also been shown to associate with hyperandrogenism (21) and obesity in adults (22), albeit that the latter effect size is moderate,

129 More recently, these studies have been extended to examine the influence of intra-uterine
130 androgen exposure on neurodevelopmental outcomes in the children of mothers with PCOS.
131 Brain development is influenced significantly by exposure to androgens during early gestation.
132 Female rhesus monkeys exposed *in utero* to androgens show increased male-type behavior (23)
133 whilst both attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder is
134 more likely to be diagnosed in males than females (24, 25). These observations suggest that
135 ADHD and ASD may be influenced by prenatal androgen exposure. One small case-control
136 study has suggested that women with PCOS may have higher scores on ADHD symptoms on
137 self-report scales (26) whilst we have recently shown that white matter microstructure is altered
138 in young women with PCOS (27). Most recently, Kosidou *et al*, in a matched case-control
139 study, found that maternal PCOS increased the odds of ASD in the children by 59%, which
140 was further exacerbated by concomitant obesity (28). These studies require confirmation but
141 suggest that PCOS may represent a novel risk-state for later life neurodevelopmental disorders.
142
143 Although these observations suggest that PCOS may be associated with several adverse mental
144 health outcomes, many studies are limited by a failure to match for obesity (a potential major
145 confounder), small sample sizes, cross-sectional study designs and assessment of psychiatric
146 morbidity using rating scales, rather than formal diagnosis by a psychiatrist or other clinician.
147 In light of these uncertainties, we sought to establish the relative risks of major mental health
148 outcomes (depressive disorder, anxiety, bipolar disorder, schizophrenia, eating disorder,
149 ADHD and ASD) for patients with PCOS, and neurodevelopmental disorders (ASD and
150 ADHD) in children born to mothers with PCOS.
151

Materials and Methods

The study employed a retrospective cohort design using data from the Clinical Practice Research Datalink (CPRD), a longitudinal, anonymized research database collected from 674 primary care practices in the United Kingdom. The CPRD contains records for over 11 million patients and is representative of the UK population in terms of age and sex (29). Approximately 60% of practices participate in a linkage scheme, by which their patient records are linked to other data sources, including the Hospital Episode Statistics (HES) dataset, which provides data on all inpatient and outpatient contacts occurring within National Health Service hospitals in England, and the Office for National Statistics (ONS) mortality dataset. Diagnostic information in the CPRD primary-care dataset is recorded using the Read code classification, a UK primary-care practice standard. HES inpatient data are recorded using the ICD-10 classification.

Patient selection and matching of controls

The study was conducted using data from CPRD's primary-care (GOLD) and linked HES data sets. The study population were those patients flagged by CPRD as being of an acceptable research quality. Patients with a diagnosis of PCOS recorded in the primary care dataset using the Read code classification (C164.00, C164.12, C165.00) from 2000 to 2014 were selected. The earliest diagnosis date was selected as the index date. A minimum "wash-in" period of 6 months from the patient's practice registration date to index date was used to maximize the likelihood that the case represented an incident case.

Patients identified with PCOS were matched at a ratio of 1:1 to two sets of non-PCOS controls. This was to allow for the baseline prevalence of the selected outcomes for patients with PCOS to be calculated relative to non-PCOS controls using matching criteria 1. Matching criteria 2 allowed for patients to be matched on mental health history to identify the incidence of outcomes following PCOS diagnosis. For control set 1, cases with PCOS were matched to controls with no history of PCOS; the controls took the index date of the case. All controls were required to have at least a 6-month wash-in period from registration at the practice to the case index date. Controls were matched by age (± 2 years), BMI category (<25 kg/m^2, 25-30 kg/m^2, >30 kg/m^2) and primary care practice. The same matching criteria were applied to control set 2, who were additionally matched for a history of prior mental health disorder (depression, anxiety, bipolar disorder, schizophrenia, eating disorder, autism, ADHD). Controls could appear in both sets. Mental health disorders were defined by the Read code

186 classification or 10th revision of the International Statistical Classification of Diseases and
187 Related Health Problems (ICD-10) classification (Supplementary appendix 1).

188

189 *Endpoints*

190 Primary outcomes were the incidence of depressive disorder, anxiety, bipolar disorder,
191 schizophrenia, eating disorder, ADHD and autism spectrum disorder in cases and controls.
192 Secondary outcomes were the prevalence of ADHD or autism spectrum disorder in the children
193 of mothers with PCOS. Children were identified via the mother-baby link generated within
194 CPRD which links mothers with their children. To maximize patient numbers, births both
195 before and after index date were included in this study.

196

197 *Data analysis*

198 Baseline characteristics between cases and controls were compared using univariate statistics
199 (t-test for continuous variables and χ^2 for categorical variables). Crude rates of progression to
200 each outcome were presented and time to each endpoint was analyzed using Cox proportional
201 hazard models (CPHM). The Cox models included the following covariates (all were available
202 and tested for inclusion in each model): age, BMI, smoking status, baseline morbidity
203 represented by the Charlson index (30), total number of contacts with the general practitioner
204 in the year before index date that is regarded as a proxy for general morbidity, and deprivation
205 based on quintiles of Index of Multiple Deprivation (IMD). The IMD is an area-based measure
206 of social and material deprivation based upon various criteria including income and education.
207 Covariates were entered into each model if they were significant in that model. Threshold
208 statistical significance was p ≤0.05, and 95% confidence intervals (CI) were given for hazard
209 ratios (HR).
210 Multivariate logistic regression was used to examine the association of PCOS status with risk
211 of autism spectrum disorder and ADHD in the children.

212

213 A sensitivity analysis exploring the association of bipolar disorder with PCOS was undertaken,
214 excluding cases who had been treated with valproate therapy prior to index date.

215

216 Studies using CPRD are covered by ethics approval granted by Trent Multicentre Research
217 Ethics Committee (Reference 05/MRE04/87). CPRD Independent Scientific Advisory
218 Committee approval was granted for this study (ISAC 16-249).

219

Results

89,732 patients with PCOS were initially identified. After application of the inclusion/exclusion criteria, 16,986 patients remained eligible for matching with control subjects (figure 1). 16,938 (99.7%) and 16,355 (96.3%) patients could be matched with controls for control sets 1 and 2 respectively.

Baseline characteristics

The baseline characteristics of patients with PCOS and controls are shown in tables 1 and 2 respectively for control sets 1 and 2. For control set 1, median follow-up was 3.87 years (interquartile range (IQR) 1.80-7.25) for cases and 2.81 years (IQR 1.20-5.80) for controls. For control set 2, median follow-up was 3.88 years (IQR 1.81-7.26) for cases and 3.07 years (IQR 1.32-6.70) for controls. In both control sets, there were significant differences between cases and controls. Patients with PCOS had increased primary care contacts in the year prior to index date (median 6.0 contacts versus 4.0 for both control sets), and an increased proportion of patients classified with extreme obesity (6.7% vs 3.9% in control set 1 and 6.3% vs 3.8% in control set 2). In addition, there were significant differences in smoking status, alcohol history and systolic and diastolic blood pressure.

Prevalence of mental health disorders

In control set 1, 3,912 (23.1%) patients with PCOS had previously been diagnosed with depression compared to 3,272 (19.32%) of controls ($p < 0.00001$) (Supplementary appendix 2). A prior diagnosis of anxiety was also higher in patients with PCOS (n=1,956, 11.55%) compared to controls (n=1,579, 9.32%) ($p < 0.00001$). There was also a significant increase in the recorded diagnosis of bipolar disorder (PCOS 535 (3.16%) vs 384 (1.45%) controls, $p < 0.00001$). Prior diagnosis of eating disorder for patients with PCOS was higher (n=262, 1.55%) than controls (n=175, 1.03%) ($p = 0.00003$). In the sensitivity analysis excluding pairs of cases and controls where either had been treated with valproate therapy prior to index date, the rate of bipolar disorder remained significantly greater for patients with PCOS (526 (3.14%) versus 375 (1.45%); $p < 0.00001$).

There were no significant differences in the prevalence of schizophrenia, autism spectrum disorder or ADHD between cases and controls (Supplementary appendix 2).

254   *Incidence of mental health disorders*

255   For control set 1 the rate of depression following index date was 42.62 per 1,000 patient years

256   (pky) for patients with PCOS compared with 34.46 pky for controls. The respective figures for

257   anxiety, bipolar disorder and eating disorder were 21.99 pky versus 17.61 pky, 4.83 pky versus

258   3.64 pky, and 7.57 pky versus 4.36 pky (Table 3). For control set 2 the rates were 41.66 pky

259   versus 26.66 pky for depression, 21.33 pky versus 12.64 pky for anxiety, 4.42 pky versus 2.48

260   pky for bipolar disorder, and 7.40 pky versus 3.95 pky for eating diosorder.

261

262

263   *Hazard ratios for mental health disorders*

264   Time to event for depression and anxiety for both control sets are shown in the Kaplan-Meier

265   curves in figure 2. After adjusting for demographic and morbidity indicators in the Cox

266   proportional hazards model, the hazard ratios for patients with PCOS compared to controls in

267   control set 1 were 1.26 (95% CI 1.19-1.32) for depression, 1.20 (95% CI 1.11-1.29) for anxiety,

268   1.21 (95% CI 1.03 – 1.42) for bipolar disorder and 1.37 (95% CI 1.05-1.81) for eating disorder.

269   For control set 2 the hazard ratios were 1.38 (95% CI 1.30-1.45) for depression, 1.39 (95% CI

270   1.29-1.51) for anxiety and 1.54 (95% CI 1.16-2.05) for eating disorder. Due to model violations

271   it was not possible to calculate the hazard ratio for bipolar disorder (Table 3).

272

273   In the sensitivity analysis excluding cases who had been treated with valproate therapy prior to

274   index date the HR for cases to controls for bipolar disorder was 1.21 (95% CI 1.03-1.42) for

275   control set 1 and 1.45 (95% CI 1.21-1.73) for control set 2.

276

277   *ADHD and Autism Spectrum Disorder in children of patients with PCOS*

278   In control set 1 there were 8,962 children born to patients with PCOS compared to 8,885 born

279   to the controls. The respective rate of ADHD was 4.81 pky versus 3.32 pky with an odds ratio

280   of 1.64 (95% CI 1.16-2.33). The rate of ASD was 5.82 pky versus 3.92 pky; odds ratio 1.54

281   (95% CI 1.12-2.11). In control set 2, there were 8,695 births to women with PCOS and 8,973

282   to controls. The rate of ADHD was 6.00 pky versus 3.54 pky; odds ratio 1.75 (1.27 – 2.46) and

283   the rate of ASD was 4.44 pky versus 3.90 pky; odds ratio 1.34 (95% CI 0.96-1.89) (Table 4).

284

285

Discussion

In this large retrospective database analysis we have reported a significantly increased prevalence of depression, anxiety, bipolar disorder and eating disorder at the time of diagnosis with PCOS compared to matched controls. There was no difference in rates of clinically recorded ASD, ADHD or schizophrenia, though the background rate of these conditions resulted in the study being under-powered for these conditions. The incidence of these conditions following index date was also increased for patients with PCOS. In addition, we have reported increased rates of ASD and ADHD in the children of women with PCOS compared with controls.

Our findings of an increased prevalence of depression and anxiety in women with PCOS are consistent with a number of cross-sectional studies using screening tools such as the Beck Depression/Anxiety Inventory or the Hospital Anxiety and Depression Scale (HADS). This risk is maintained even when only moderate-to-severe symptoms are considered and when the diagnosis is made by a psychiatrist (31, 32). We also observed an increased incidence of depression and anxiety when we matched patients and controls for a prior history of mental health disorder. Similarly increased risks of developing depression and anxiety with time have been found in Taiwanese (17) and Australian (33) patients with PCOS.

A number of potential mechanisms may be in operation. Obesity, which is itself associated with depression and anxiety (9, 10), is a common co-morbidity in women with PCOS and could explain some of this risk. However, in a systematic review and meta-analysis of cross-sectional studies (32), the increased odds of depressive and anxiety symptoms persisted even when subjects with PCOS were matched on BMI with controls, indicating that factors other than obesity must be contributing. Hyperandrogenism is a hallmark of PCOS and may lead to the emotionally distressing symptoms of hirsutism and acne. High patient-rated Ferriman-Gallwey scores, as a measure of hirsutism, have been associated with higher HADS depression and anxiety scores in women presenting to dermatology clinics for hair removal (34). Ferriman-Gallwey scores were also increased in PCOS subjects with anxiety and depression symptoms, and free testosterone levels were higher in women with PCOS and anxiety compared to those with no anxiety (32). However, the relationship between androgen levels and affective symptoms may not be so clear-cut since others have shown an association of *lower* testosterone and androgen metabolite concentrations with worse self-reported depression symptoms in women with PCOS (35). Increased changes in testosterone concentrations across the

320 perimenopause have also been associated with depression (36, 37). Fertility may be another

321 major concern for women with PCOS, although depression and anxiety scores remain higher

322 than controls in studies where this has been accounted for (32, 38). Of interest, insulin

323 resistance has also been proposed as a potential mechanism by which depression and anxiety

324 might be increased in PCOS. Insulin resistance, a characteristic of both lean and overweight

325 patients with PCOS, shows a bidirectional relationship with depression in the general

326 population (39) whilst in a recent study of PCOS subjects, insulin resistance was associated

327 with depression risk independently of age, BMI, ethnicity and exercise (40).

328

329 In contrast to depression and anxiety, only a few studies have examined the risk of other

330 psychiatric disorders in women with PCOS. However, two population-based studies have

331 shown that the risk of mental health disorders in PCOS may be broader than previously

332 recognized, with increased odds of bipolar disorder, schizophrenia, personality disorders,

333 autism spectrum disorder, bulimia and tics, in addition to depression and anxiety (17, 41).

334 Whilst we were underpowered to show an effect of PCOS on autism spectrum disorder, ADHD

335 and schizophrenia, we did confirm an increased prevalence and incidence of bipolar disorder

336 compared to matched controls. Valproate therapy could, at least in part, explain this association

337 since symptoms compatible with PCOS have been reported in women treated for bipolar

338 disorder with valproate (42). However, other studies have shown that symptoms pre-date

339 treatment (43). Furthermore, in keeping with another registry study (41) we found that this

340 association, although slightly attenuated, persisted when excluding subjects treated with

341 valproate before diagnosis. The prevalence and incidence of eating disorder was also higher in

342 patients with PCOS. This is in keeping with other studies (19, 20), which have shown an

343 association of binge-eating with menstrual dysfunction (44), and a higher rate of eating

344 disorders in women with PCOS especially in the presence of concurrent anxiety (20).

345

346 Since the intra-uterine environment is known to be important in regulating child

347 neurodevelopment, we were also keen to examine the effect of maternal PCOS status (and

348 potential hyperandrogenism) on the risk of neurodevelopmental disorders in their children. Our

349 linkage analysis found an increased risk of a recorded diagnosis of ASD and ADHD in children

350 born to mothers with PCOS. This is in agreement with the observations of Kosidou *et al* (25,

351 45), who reported respectively increased risks of 59% and 42%, of a similar magnitude to our

352 data. They have recently extended their observations in relation to ASD to report an increased

353 risk in mothers with a diagnosis of hirsutism (46). These data support the view that increased

354   exposure to androgens *in utero* might adversely influence brain development. Indeed, intra-

355   amniotic Δ4 sex-steroid levels, including testosterone and androstenedione, were found to be

356   higher in mothers of children who subsequently developed ASD than those who did not (47).

357   PCOS might expose the developing fetus to excess androgens since women with PCOS show

358   increased circulating androgen levels during gestation and have greater placental androgenic

359   capacity (48-50). Prenatal androgen exposure might increase ASD and ADHD risk through

360   effects on dendritic morphology, neuronal density, abnormal synapse function and morphology

361   (51, 52). In this regard, our recent findings of altered white matter microstructure in women

362   with PCOS, notably in androgen-sensitive areas such as the corpus callosum (27), are

363   intriguing and merit further investigation. Maternal androgen excess might also predispose to

364   anxiety in the children of mothers with PCOS: in a rodent model, prenatal androgen exposure

365   resulted in increased anxiety-like behavior in offspring, mediated via androgen receptor

366   activation in the amygdala and accompanied by changes in serotonergic and GABAergic genes

367   in the amygdala and hippocampus (53).

368

369   Whilst environmental influences such as androgen exposure may go some way to explaining

370   the effects of PCOS on mental health risk, other explanations for these findings also merit

371   consideration. In a nationwide Swedish registry study, Cesta *et al* found a higher risk for a

372   range of psychiatric disorders not only in PCOS subjects but also in their siblings (41).

373   Endocrine disturbances could account for these findings since nearly 50% of sisters of women

374   with PCOS are hyperandrogenic (54) whilst their brothers also have alterations in gonadotropin

375   and steroidogenic hormone secretion (55). Alternatively, shared familial factors between

376   PCOS and psychiatric disorders may exist, including a common genetic predisposition as well

377   as shared psychosocial factors in childhood.

378

379   Our study has a number of strengths, especially the large, population-based sample and

380   adjustment for a number of potential confounders. However, our study also has limitations. As

381   with all database studies, there is the possibility of confounding and bias that should be

382   considered when interpreting these results. Patients with PCOS had significantly increased

383   primary care contacts in the 12 months prior to baseline (6 versus 4 in both control sets). This

384   may be due to consultations relating to symptoms and investigations relevant to the PCOS

385   diagnosis, but they may also relate to the prevalence of other conditions which may be

386   associated with other health-related morbidities.

387

388   Observation bias may also be a factor in these results, as patients with increased contacts with
389   health professionals necessitated by the presence of a condition such as PCOS have increased
390   chance of other conditions such as depression and anxiety being diagnosed and recorded within
391   the dataset. We deliberately used a broad range of codes to determine depression and anxiety
392   as there is evidence that over the study time period there has been a shift in primary care such
393   that the recording of clinical diagnoses of depression has reduced whilst the recording of
394   depressive symptoms has increased. Overall, however, the combined rate for the incidence of
395   diagnoses and symptoms has remained relatively stable (56). It is possible, however, that some
396   symptom terms such as 'Feeling depressed' may be less indicative of clinically relevant
397   depression than diagnosis terms such as 'Chronic depression'. Whilst there may be some
398   ambiguity surrounding depression and anxiety this is less likely for bipolar disorder which was
399   increased in the population with PCOS compared with controls.
400
401   There was significant missing data in this study. Body mass index was not available for over
402   50% of cases although obesity is known to be associated with depression and anxiety (9, 10)
403   and also with PCOS. To compensate for this we modelled BMI as a categorical variable with
404   missing included as a category, but it should be considered that different levels of BMI within
405   the 'missing' category could partially explain some of the observed results in this study.
406
407   In conclusion, our study confirms that women with PCOS are at increased risk of being
408   diagnosed with depression, anxiety, bipolar disorder and eating disorder, and that their children
409   are at increased risk of a diagnosis of autism spectrum disorder and ADHD. Our data support
410   international guidelines which recommend screening for mental health disorders as part of the
411   comprehensive clinical care for women with this condition (57, 58). Further research is critical
412   in understanding the mechanisms by which these risks arise in order to optimise interventions
413   to reduce psychiatric morbidity.
414
415
416
417

418   **References**
419   1. Rees DA, Jenkins-Jones S, Morgan CL. Contemporary reproductive outcomes for patients
420   with Polycystic Ovary Syndrome: a retrospective, observational study. J Clin Endocrinol
421   Metab 2016; 101(4):1664-72.
422

423 2. Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young
424 women with polycystic ovary syndrome versus matched, reference controls: a retrospective
425 observational study. J Clin Endocrinol Metab 2012;97(9):3251-60.
426
427 3. Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M. Quality of life of hirsute women.
428 Postgrad Med J 1993;69:186-189.
429
430 4. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of
431 life in acne: a comparison with general medical conditions using generic questionnaires. Br J
432 Dermatol 1999;140(4):672-6.
433
434 5. Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common
435 risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28
436 studies. Hum Reprod Update 2012; 18(6):638-51.
437
438 6. Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary
439 syndrome: a systematic review and meta-analysis. Hum Reprod 2011;26(9):2442-51.
440
441 7. Dokras A, Clifton S, Futterweit RW, Wild R. Increased risk for abnormal depression scores
442 in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet
443 Gynecol 2011;117(1):145-52.
444
445 8. Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in
446 women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril.
447 2012;97(1):225-30 doi:10.1016/j.fertnstert.2011.10.022.
448
449 9. Acmaz G, Albayrak E, Acmaz B, Baser M, Soyak M, et al (2013). Level of anxiety,
450 depression, self-esteem, social anxiety, and quality of life among the women with polycystic
451 ovary syndrome. Scientific World Journal 2013:851815.
452
453 10. Dawes AJ, Maggard-Gibbons M, Maher AR, Booth MJ, Miake-Lye I, Beroes JM, Shekelle
454 PG. Mental health conditions among patients undergoing bariatric surgery: a meta-analysis.
455 JAMA 2016:315(2):150-63.
456
457 11. Burke NL, Storch EA. A meta-analysis of weight status and anxiety in children and
458 adolescents. J Dev Behav Pediatr 2015;36(3):133-45.
459
460 12. Jokela M, Hamer M, Singh-Manoux A, Batty GD, Kivimäki M. Association of
461 metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies. Mol
462 Psychiatry 2014;19(8):910-4.
463
464 13. Xu Q, Anderson D, Lurie-Beck J. The relationship between abdominal obesity and
465 depression in the general population: a systematic review and meta-analysis. Obes Res Clin
466 Pract 2011; 5(4):e267-360.
467
468 14. De Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and
469 obesity: a meta-analysis of community-based studies. Psychiatry Res 2010; 178(2):230-5.
470

471   15. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG.
472   Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal
473   studies. Arch Gen Psychiatry 2010;67(3):220-9.
474
475   16. Blaine B. Does depression cause obesity?: A meta-analysis of longitudinal studies of
476   depression and weight control. J Health Psychol 2008:13(8):1190-7.
477
478   17. Markham JA. Sex steroids and schizophrenia. Rev Endocr Metab Disord. 2012;13(3):187-
479   207.
480
481   18. Hung JH, Hu LY, Tsai SJ, Yang AC, Huang MW, Chen PM, Wang SL, Lu T, Shen CC.
482   Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-
483   based cohort study. PLoS One 2014;9(5):e97041.
484
485   19. Annagür BB, Kerimoglu ÖS, Tazeqül A, Gündüz Ş, Gençoglu BB. Psychiatric comorbidity
486   in women with polycystic ovary syndrome. J Obstet Gynaecol Res 2015;41(8):1229-33.
487
488   20. Lee I, Cooney LG, Saini S, Smith ME, Sammel MD, Allison KC, Dokras A. Increased risk
489   of disordered eating in polycystic ovary syndrome. Fertil Steril 2017; 107(3):796-802.
490
491   21. Mueller SC, Ng P, Sinaii N, Leschek EW, Green-Golan L, Van Ryzin C, Ernst M, Merke
492   DP. Psychiatric characterization of children with genetic causes of hyperandrogenism. Eur J
493   Endocrinol 2010;163(5):801-10.
494
495   22. Nigg JT, Johnstone JM, Musser ED, Long HG, Willoughby MT, Shannon J. Attention-
496   deficit/hyperactivity disorder (ADHD) and being overweight/obesity: New data and meta-
497   analysis. Clin Psychol Rev 2016; 43:67-79.
498
499   23. Hines M. Early androgen influences on human neural and behavioral development. Early
500   Hum Dev 2008;84:805-807.
501
502   24. Rucklidge JJ. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr Clin
503   North Am 2010;33:357-373.
504
505   25. Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, Knickmeyer R.
506   Why are autism spectrum conditions more prevalent in males? PLoS Biol 2011;9:e1001081.
507
508   26. Hergüner S, Harmanaci H, Toy H. Attention deficit-hyperactivity disorder symptoms in
509   women with polycystic ovary syndrome. Int J Psych Med 2015;50(3):317-325.
510
511   27. Rees DA, Udiawar M, Berlot R, Jones DK, O'Sullivan MJ. White matter microstructure
512   and cognitive function in young women with polycystic ovary syndrome. J Clin Endocrinol
513   Metab 2016;101(1):314-323.
514
515   28. Kosidou K, Dalman C, Widman L, Arver S, Lee BK, Magnusson C, Gardner RM. Maternal
516   polycystic ovary syndrome and the risk of autism spectrum disorders in the children: a
517   population-based   nationwide   study   in   Sweden.   Mol   Psychiatry   2015   doi:
518   10.1038/mp.2015.183 [EPub ahead of print].
519

520 29. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data
521 Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-
522 36.
523
524 30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
525 comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-
526 383.
527
528 31. Cooney LG, Dokras A. Depression and anxiety in polycystic ovary syndrome: etiology and
529 treatment. Curr Psychiatry Rep 2017;19:83
530
531 32. Cooney LG, Lee I, Samuel MD, Dokras A. High prevalence of moderate and severe
532 depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-
533 analysis. Hum Reprod 2017a;32:1075-91.
534
535 33. Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman's long-
536 term health using data linkage. J Clin Endocrinol Metab 2015;100:911-9.
537
538 34. Ekback MP, Lindberg M, Benzein E, Arestedt K. Health-related quality of life, depression
539 and anxiety correlate with the degree of hirsutism. Dermatology 2013;227:278-84.
540
541 35. Jedel E, Gustafson D, Waern M, Sverrisdottir YB, Landén M, Janson PO, Labrie F, Ohlsson
542 C, Stener-Victorin E. Sex steroids, insulin sensitivity and sympathetic nerve activity in relation
543 to affective symptoms in women with polycystic ovary syndrome. Psychoneuroendocrinology
544 2011;36(10):1470-9.
545
546 36. Milman LW, Sammel MD, Barnhart KT, Freeman EW, Dokras A. Higher serum total
547 testosterone levels correlate with increased risk of depressive symptoms in Caucasian women
548 through the entire menopausal transition. Psychoneuroendocrinology 2015;62:107-13.
549
550 37. Bromberger JT, Schott LL, Kravitz HM, Sowers M, Avis NE, Gold EB, Randolph JF Jr,
551 Matthews KA. Longitudinal change in reproductive hormones and depressive symptoms across
552 the menopausal transition: results from the Study of Women's Health Across the Nation
553 (SWAN). Arch Gen Psychiatry 2010;67(6):598-607.
554
555 38. Shi X, Zhang L, Fu S, Li N. Co-involvement of psychological and neurological
556 abnormalities in infertility with polycystic ovarian syndrome. Arch Gynecol Obstet
557 2011;284:773-8.
558
559 39. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the
560 lifespan: a meta-analysis. Diabetes Care 2008;31:383-90.
561
562 40. Greenwood EA, Pasch LA, Shinkai K, Cedars MI, Huddleston HG. Putative role for insulin
563 resistance in depression risk in polycystic ovary syndrome. Fertil Steril 2015;104:707-14.e1.
564
565 41. Cesta CE, Mansson M, Palm C, Lichtenstein P, Iliadou AN, Landen M. Polycystic ovary
566 syndrome and psychiatric disorders: co-morbidity and heritability in a nationwide Swedish
567 cohort. Psychoneuroendocrinology 2016;73:196-203.
568

569 42. Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Hwang CH, Hall JE,
570 Sachs GS. Valproate is associated with new-onset oligoamenorrhoea with hyperandrogenism
571 in women with bipolar disorder. Biol Psychiatry 2006;59:1078-1086.
572
573 43. Reynolds-May MF, Kenna HA, Marsh W, Stemmle PG, Wang P, Ketter TA, Ragson NL.
574 Evaluation of reproductive function in women treated for bipolar disorder compared to healthy
575 controls. Bipolar Disord 2014;16:37-47.
576
577 44. Algars M, Huang L, Von Holle AF, Peat CM, Thornton LM, Lichtenstein P, Bulik CM.
578 Binge eating and menstrual dysfunction. J Psychosom Res 2014;76(1):19-22.
579
580 45. Kosidou K, Dalman C, Widman L, Arver S, Lee BK, Magnusson C, Gardner RM. Maternal
581 polycystic ovary syndrome and risk for attention deficit/hyperactivity disorder in the offspring.
582 Biol Psychiatry 2017;82(9):651-659.
583
584 46. Lee BK, Arver S, Widman L, Gardner RM, Magnusson C, Dalman C, Kosidou K. Maternal
585 hirsutism and autism spectrum disorders in offspring. Autism Res 2017;10(9):1544-1546.
586
587 47. Baron-Cohen S, Auyeung B, Norgaard-Pedersen B, Hougaard D, Abdallah M, Melgaard
588 L,Cohen AS, Chakrabarti B, Ruta L, Lombardo MV. Elevated fetal steroidogenic activity in
589 autism. Mol Psychiatry 2015;20(3):369-76.
590
591 48. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal
592 serum androgens in pregnant women with polycystic ovary syndrome: possible implications in
593 prenatal androgenisation. Hum Reprod 2002;17:2573-2579.
594
595 49. Maliqueo M, Lara HE, Sanchez F, Echiburu B, Crisosto N, Sir-Petermann T. Placental
596 steroidogensis in pregnant women with polycystic ovary syndrome. Eur J Obstet Gynecol
597 Reprod Biol 2013;166:151-155.
598
599 50. Maliqueo M, Sundström Poromaa I, Vanky E, Fornes R, Benrick A, Akerud H, Stridsklev
600 S, Labrie F, Jansson T, Stener-Victorin E. Placental STAT3 signaling is activated in women
601 with polycystic ovary syndrome. Hum Reprod 2015;30(3):692-700.
602
603 51. McCarthy MM, Arnold AP. Reframing sexual differentiation of the brain. Nat Neurosci
604 2011;14:677-683.
605
606 52. Olde Loohuis NF, Kole K, Glennon JC, Karel P, Van der Borg G, Van Gemert Y, Van den
607 Bosch D, Meinhardt J, Kos A, Shahabipour F, Tiesinga P, van Bokhoven H, Martens GJ,
608 Kaplan BB, Homberg JR, Aschrafi A. Elevated microRNA-181c and microRNA-30d levels in
609 the enlarged amygdala of the valproic acid rat model of autism. Neurobiol Dis 2015;80:42-53.
610
611 53. Hu M, Richard JE, Maliqueo M, Kokosar M, Fornes R, Benrick A, Jansson T, Ohlsson C,
612 Wu X, Skibicka KP, Stener-Victorin E. Maternal testosterone exposure increases anxiety-like
613 behavior and impacts the limbic system in the offspring. Proc Natl Acad Sci USA
614 2015;112(46):14348-53.
615
616 54. Legro RS, Driscoll D, Strauss 3rd JF, Fox J, Dunaif A. Evidence for a genetic basis for
617 hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998;95:14956-
618 14960.

619
620 55. Liu DM, Torchen LC, Sung Y, Paprodis R, Legro RS, Grebe SK, Singh RJ, Taylor RL,
621 Dunaif A. Evidence for gonadotrophin secretory and steroidogenic abnormalities in brothers
622 of women with polycystic ovary syndrome. Hum Reprod 2014;29:2764-2772.
623
624 56. Rait J, Walters K, Griffin M, Buszewicz M, Petersen I, Nazareth I. Recent trends in the
625 incidence of recorded depression in primary care. Br J Psychiatry 2009;195(6):520-4.
626
627 57. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R; Endocrine
628 Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical
629 practice guideline. J Clin Endocrinol Metab 2013;98(12):4565-92.
630
631 58. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, Norman RJ, Costello
632 MF; Guideline Development Groups. Assessment and management of polycystic ovary
633 syndrome: summary of an evidence-based guideline. Med J Aust 2011;195(6):S65-112.

634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664 **Tables and figures**
665
666 **Table 1** *Baseline characteristics for women with PCOS and matched controls – control set 1*

Baseline Characteristics	Case		Control		p-value
Total, n (%)	16,938	100.00	16,938	100.00	
Age (years), mean, SD	26.90	7.20	27.01	7.36	0.1983
Follow-up (years), median, LQ-UQ	3.87	1.80 - 7.25	2.81	1.20 - 5.80	<0.0001
Observation period pre-index (years), median, LQ-UQ	4.33	1.90 - 9.10	3.32	1.48 - 7.59	<0.0001
Primary care contact in prior year, median, LQ-UQ	6	3 - 9	4	1 - 7	<0.0001
BMI (kg/m^2), mean, SD	29.86	7.86	28.99	7.01	<0.0001
BMI (kg/m^2)					<0.0001
Underweight, (<20), n(%)	653	3.86	663	3.91	
Normal, (20-24), n(%)	1,652	9.75	1,683	9.94	
Overweight, (>24-29), n(%)	1,885	11.13	1,938	11.44	
Obesity, (>29-39), n(%)	2,955	17.45	3,335	19.69	
Extreme Obesity, (>39), n(%)	1,133	6.69	659	3.89	
Missing, n(%)	8,660	51.13	8,660	51.13	
Smoking					<0.0001
Never, n(%)	10,540	62.23	10,333	61	
Prior, n(%)	2,934	17.32	2,559	15.11	
Current, n(%)	4,394	25.94	4,918	29.04	
Missing, n(%)	174	1.03	727	4.29	
Alcohol					<0.0001
Never, n(%)	3,525	20.81	3,181	18.78	
Prior, n(%)	240	1.42	229	1.35	
Current, n(%)	9,713	57.34	9,812	57.93	
Missing, n(%)	3,460	20.43	3,716	21.94	
Diastolic BP					<0.0001
Diastolic BP (mmHg), mean, SD	74.97	9.82	73.52	9.55	<0.0001
<80, n(%)	6,128	36.18	6,878	40.61	
80-89,n(%)	2,913	17.2	2,783	16.43	
>89, n(%)	697	4.12	468	2.76	
Missing, n(%)	7,200	42.51	6,809	40.2	
Systolic BP					<0.0001
Systolic BP (mmHg), mean, SD	118.78	13.78	117.89	13.26	<0.0001
<120, n(%)	4,782	28.23	5,201	30.71	
120-139, (%)	4,170	24.62	4,286	25.3	
>139, n(%)	786	4.64	642	3.79	
Missing, n(%)	7,200	42.51	6,809	40.2	

668 **Table 2** *Baseline characteristics for women with PCOS and matched controls – control set 2*

669

Baseline Characteristics	Case		Control		p-value
Total, n(%)	16,355	100.00	16,355	100.00	
Age (years), mean, SD	26.93	7.21	27	7.37	0.3997
Follow-up (years), median, LQ-UQ	3.88	1.81 - 7.26	3.07	1.32 - 6.70	<0.0001
Observation period pre-index (years), median, LQ-UQ	4.30	1.89 - 9.05	3.67	1.63 - 8.13	<0.0001
Primary care contact in prior year, median, LQ-UQ	6	3 - 9	4	1 - 7	<0.0001
BMI (kg/m^2), mean, SD	29.68	7.83	28.84	7.07	<0.0001
BMI (kg/m^2)					<0.0001
Underweight, (<20), n(%)	632	3.86	664	4.06	
Normal, (20-24), n(%)	1,600	9.78	1,594	9.75	
Overweight, (>24-29), n(%)	1,789	10.94	1,842	11.26	
Obesity, (>29-39), n(%)	2,721	16.64	3,052	18.66	
Extreme Obesity, (>39), n(%)	1,027	6.28	617	3.77	
Missing, n(%)	8,586	52.5	8,586	52.5	
Smoking					<0.0001
Never, n(%)	10,051	61.46	10,231	62.56	
Prior, n(%)	2,459	15.04	2,970	18.16	
Current, n(%)	4,185	25.59	4,652	28.44	
Missing, n(%)	170	1.04	749	4.58	
Alcohol					<0.0001
Never, n(%)	3,403	20.81	3,052	18.66	
Prior, n(%)	218	1.33	237	1.45	
Current, n(%)	9,378	57.34	9,342	57.12	
Missing, n(%)	3,356	20.52	3,724	22.77	
Diastolic BP					<0.0001
Diastolic BP (mmHg), mean, SD	74.9	9.82	73.27	9.58	<0.0001
<80, n(%)	5,887	36	6,765	41.36	
80-89, n(%)	2,773	16.96	2,496	15.26	
>89, n(%)	652	3.99	464	2.84	
Missing, n(%)	7,043	43.06	6,630	40.54	
Systolic BP					<0.0001
Systolic BP (mmHg), mean, SD	118.71	13.78	117.85	13.06	<0.0001
<120, n(%)	4,576	27.98	4,999	30.57	
120-139, (%)	3,991	24.4	4,110	25.13	
>139, n(%)	745	4.56	616	3.77	
Missing, n(%)	7,043	43.06	6,630	40.54	

670

Table 3 *Number, crude rates and associated hazard ratios for depression, anxiety and bipolar disorder in women with PCOS and matched controls*

	Cases		Controls		Hazard Ratio (CI)	p-value
	Number	**(Rate pky)**	**Number**	**(Rate pky)**		
Control set 1	16,938		16,938			
Depression	3,545	42.62	2,327	34.46	1.26 (1.19 – 1.32)	<0.00001
Anxiety	1,829	21.99	1,189	17.61	1.20 (1.11 – 1.29)	<0.00001
Bipolar Disorder	402	4.83	246	3.64	1.21 (1.03 – 1.42)	0.02126
Autism	14	0.83	16	0.94		
ADHD	13	0.77	11	0.65		
Schizophrenia	22	1.30	9	0.53		
Eating Disorder	125	7.57	72	4.36	1.37 (1.05 – 1.81)	0.02283
Control set 2	16,355		16,355			
Depression	3,353	41.66	2,146	26.66	1.38 (1.30 – 1.45)	<0.00001
Anxiety	1,717	21.33	1,017	12.64	1.39 (1.29 – 1.51)	<0.00001
Bipolar Disorder	356	4.42	200	2.48		
Autism	9	0.55	3	0.18		
ADHD	8	0.49	6	0.37		
Schizophrenia	10	0.61	6	0.37		
Eating Disorder	118	7.40	63	3.95	1.54 (1.16 - 2.05)	0.00256

pky: per 1,000 person years

Table 4 *Number, rate and odds ratio of ADHD and autism in the children of mothers with PCOS and matched controls*

Mental Health Disorder	Cases		Controls		Odds Ratio (CI)	p-value
	Number	(Rate pky)	Number	(Rate pky)		
Control set 1	8,962		8,885			
ADHD	81	4.81	56	3.32	1.64 (1.16 – 2.33)	0.00526
Autism	98	5.82	67	3.98	1.54 (1.12 – 2.11)	0.00068
Control set 2	8,695		8,973			
ADHD	74	4.44	65	3.90	1.34 (0.96 – 1.89)	0.08708
Autism	95	6.00	59	3.54	1.75 (1.27 – 2.46)	0.00080

pky: per 1,000 person years

<u>Figure 1</u> *Attrition chart for identification of pool of patients with PCOS*

Figure 2 | *Kaplan-Meier curves showing time to depression and anxiety for patients with PCOS compared to matched controls.*